Pulmonary Hypertension

PERK inhibition attenuates vascular remodeling in pulmonary arterial hypertension caused by BMPR2 mutation - Science PERK inhibition attenuates vascular remodeling in pulmonary arterial hypertension caused by BMPR2 mutation - Science Posted: 26 Jan 2021 11:14 AM PST Not a PERK for pulmonary arterial hypertension The vascular remodeling that occurs in pulmonary arterial hypertension (PAH) is eventually fatal because it leads to right ventricular heart failure. PAH induces the unfolded protein response (UPR), and Shimizu et al. focused on the role of the UPR kinase PERK in PAH pathology. Genetic ablation or pharmacological inhibition of PERK limited vascular remodeling in two different mouse models of PAH and prevented mice from developing right ventricular heart failure. These effects involved suppressing the activation of PDGFRβ-STAT1 signaling and glycolysis in pulmonary artery smooth muscle cells. Thus, targeting PERK may help limit the...

New hope against diseases marked by progressive scarring of lung tissue - Medical Xpress New hope against diseases marked by progressive scarring of lung tissue - Medical Xpress Pulmonary Hypertension Fund Opens at the HealthWell Foundation - PRNewswire Tracleer for Digital Ulcers Lowers PH Risk in Scleroderma, Study Finds - Scleroderma News Pulmonary Arterial Hypertension Epidemiology Forecast to 2030 by DelveInsight - Press Release - Digital Journal New hope against diseases marked by progressive scarring of lung tissue - Medical Xpress Posted: 15 Jan 2021 12:00 AM PST (HealthDay)—An inhaled medication might make every day physical activity a bit easier for patients with serious scarring of the lungs, a new clinical trial finds. The study, published online Jan. 13 in the New England Journal of Medicine , involved patients with high blood pressure in the lungs caused by interstitial lung disease (ILD)...

Optimism for Interstitial Lung Disease–Associated Pulmonary Hypertension? - nejm.org Optimism for Interstitial Lung Disease–Associated Pulmonary Hypertension? - nejm.org COVID Vaccine for Patient With Rare Disease? Best Guess Is Yes - MedPage Today Previous: Top 10 Pulmonary Hypertension Stories of 2020 - Pulmonary Hypertension News New Hope Against Diseases Marked by Progressive Scarring of Lung Tissue - HealthDay News Optimism for Interstitial Lung Disease–Associated Pulmonary Hypertension? - nejm.org Posted: 13 Jan 2021 12:00 AM PST Pulmonary hypertension scares us, and for good reason. Pulmonary hypertension may be caused by an intrinsic pulmonary vasculopathy — termed pulmonary arterial hypertension — or it may complicate other, more common problems such as interstitial lung disease, in which it signals the presence of advanced, often end-stage disease. 1 Regardless of its cause, without effec...

Previous: Top 10 Pulmonary Hypertension Stories of 2020 - Pulmonary Hypertension News Previous: Top 10 Pulmonary Hypertension Stories of 2020 - Pulmonary Hypertension News Posted: 04 Jan 2021 05:00 AM PST Throughout 2020, Pulmonary Hypertension News brought daily coverage of groundbreaking research, treatment advancements, and clinical trial developments related to pulmonary hypertension (PH). As we anticipate bringing you more PH news this year, we take a look back at our top 10  most-read stories of 2020, with a summary of their significance for the PH community. No. 10 — " PAH Orenitram Drug More Cost-effective Than Uptravi, Study Suggests" A study found that in people with pulmonary arterial hypertension (PAH), treatment with Orenitram (oral treprostinil ) is more cost-effective than Uptravi (selexipag). Both common treatments for PAH, the medications mimic the action of prostacyclin , a hormon...